Recombinant Cell IFT (RC-IFT) – the quickest way to bring new research parameters into the diagnostic laboratory

The production of antigens in sufficient amounts and of the desired quality is often the critical step in the development of a new test system. In particular, the purification is often difficult and causes delays in the development process. This may be due to different reasons:

  • The antigen is located in the cell membrane: To eliminate the molecule from the membrane, aggressive methods are often required which may destroy the antigen.
  • The antigen must be in its native, three-dimensional form. If the antibodies to be detected bind to conformational epitopes of the antigen, it needs to be purified in its native state, a procedure which is very complicated and complex.

In these cases, a genetic method for the production of antigens is by far quicker. In the RC-IFT method, the antigen-coding DNA sequence is inserted into a DNA molecule (plasmid) which is afterwards introduced into suitable host cells. The cells express the antigen molecule and can thus be immediately used as a substrate in the immunofluorescence test. Using this method, test systems with new antigens can be produced in a short time.

The following EUROIMMUN test systems are based on the RC-IFT method:

Recombinant Cell IFT for the detection of antibodies against:
Skin antigens: desmoglein 1 and 3, BP230, collagen VII, envoplakin*
Nephropathy-associated antigens: phospholipase A2 receptors (PLA2R)
Neuronal antigens: glutamate receptors of type NMDA, type AMPA*, VGKC, GABAB receptor, aquaporin-4, glycine receptor **, DPPX, DNER
Further antigens: pancreas antigens rPAg1 (CUZD1) and rPAg2 (GP2), glutamate decarboxylase (GAD65), Crimean-Congo fever virus

*currently not sold as IVD in the EU   **under development

Back to top